Essex Investment Management Co. LLC Sells 83,768 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Essex Investment Management Co. LLC reduced its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 11.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 623,310 shares of the company’s stock after selling 83,768 shares during the quarter. Essex Investment Management Co. LLC owned approximately 0.68% of Aquestive Therapeutics worth $2,219,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new position in Aquestive Therapeutics in the fourth quarter worth $498,000. Charles Schwab Investment Management Inc. lifted its position in Aquestive Therapeutics by 3.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company’s stock worth $750,000 after purchasing an additional 7,129 shares during the period. SBI Securities Co. Ltd. bought a new position in Aquestive Therapeutics in the fourth quarter worth $115,000. MONECO Advisors LLC bought a new position in Aquestive Therapeutics in the fourth quarter worth $156,000. Finally, New York State Common Retirement Fund lifted its position in Aquestive Therapeutics by 713.3% in the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after purchasing an additional 10,700 shares during the period. 32.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on AQST. Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price for the company. Lake Street Capital reduced their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Aquestive Therapeutics has an average rating of “Buy” and a consensus target price of $10.57.

Aquestive Therapeutics Stock Up 2.7 %

Shares of NASDAQ AQST opened at $2.65 on Monday. The firm’s 50-day simple moving average is $3.09 and its 200 day simple moving average is $4.10. The company has a market cap of $262.01 million, a price-to-earnings ratio of -5.89 and a beta of 2.76. Aquestive Therapeutics, Inc. has a 12-month low of $2.24 and a 12-month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million. On average, equities analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.